Many anti-tumor vaccines have failed in recent clinical trials because they included the wrong patients and the wrong immune adjuvants - and little was learned because the anti-tumor immune response was not carefully monitored. A new tumor vaccine for lymphoma sets the stage for how future trials should be carried out (pages 1171-1177).

Original languageEnglish
Pages (from-to)1124-1125
Number of pages2
JournalNature medicine
Issue number10
StatePublished - Oct 1999


Dive into the research topics of 'Cancer vaccine strategies get bigger and better'. Together they form a unique fingerprint.

Cite this